RCFS Winter Conference: Decisions
Decisions for submitted papers and registered reports have been sent. If you selected dual submission, you will receive a separate email in the coming weeks.
Decisions for submitted papers and registered reports have been sent. If you selected dual submission, you will receive a separate email in the coming weeks.
The 11th MoFiR Workshop on Banking is now accepting submissions. Please see the Call for Papers. The workshop, which features a dual submission option with RCFS, will take place in Lisbon on July 5-6, 2022. The RCFS sponsoring editor is Andrew Ellul. The submission deadline is 6pm (GMT), Sunday January 30, 2022.
“Do Ex-Bankers Benefit Non-Financial Firms? Evidence from Job Transitions” by Lucy Chernykh and Sergey Mityakov
The Editorial Board has received 33 Registered Reports on the subject of “Finance for the Greater Good” for the 2022 RCFS Winter Conference.
“Passivity on the Board of Directors” by Chris Yung “Racial Disparities in Mortgage Lending: New Evidence based on Processing Time” by Bin Wei Federal and Feng Zhao
The Paycheck Protection Program (PPP), with over $500 billion distributed over a few months in 2020, was one of the largest stimulus programs in U.S. history. The program was created to help “small businesses” survive the COVID-19 shock. However, in a forthcoming RCFS paper, “Public Firm Borrowers of the U.S. Paycheck Protection Program,” Anna Cororaton and Samuel Rosen document that nearly half of U.S. public firms were eligible for the… Read More »Paper Spotlight: Public Firm Borrowers of the U.S. Paycheck Protection Program
The Editor’s Choice paper for issue 10(4) is “Public Firm Borrowers of the U.S. Paycheck Protection Program” by Anna Cororaton and Samuel Rosen. You can read the paper free online.
The Editorial Board has received 457 papers for the 2022 RCFS Winter Conference.
Recent estimates suggest that the cost of developing a single new drug in the biopharmaceutical sector is $2.6 billion, confirming the very large amounts of money that medical companies invest to develop a new treatment. Biomedical companies also face the risk of very low rates of success, not only due to the inherent scientific risk of developing… Read More »Paper Spotlight: Sharing R&D Risk in Healthcare via FDA Hedges
“Hidden Performance: Salary History Bans and Gender Pay Gap” by Jesse Davis, Paige Parker Ouimet, and Xinxin Wang